Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
Total Valuation
Newron Pharmaceuticals SpA has a market cap or net worth of CHF309.59M. The enterprise value is CHF364.59M.
Market CapCHF309.59M
Enterprise ValueCHF364.59M
Share Statistics
Newron Pharmaceuticals SpA has 20,805,798 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,805,798
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Newron Pharmaceuticals SpA’s return on equity (ROE) is 1.20 and return on invested capital (ROIC) is -17.09%.
Return on Equity (ROE)1.20
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-17.09%
Return on Capital Employed (ROCE)0.47
Revenue Per Employee869.36K
Profits Per Employee-605.70K
Employee Count22
Asset Turnover0.48
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Newron Pharmaceuticals SpA is ―. Newron Pharmaceuticals SpA’s PEG ratio is 0.21.
PE Ratio―
PS Ratio26.73
PB Ratio-45.95
Price to Fair Value-45.95
Price to FCF15.73
Price to Operating Cash Flow10.15
PEG Ratio0.21
Income Statement
In the last 12 months, Newron Pharmaceuticals SpA had revenue of 19.13M and earned -13.33M in profits. Earnings per share was -0.67.
Revenue19.13M
Gross Profit19.13M
Operating Income-4.70M
Pretax Income-12.35M
Net Income-13.33M
EBITDA-4.55M
Earnings Per Share (EPS)-0.67
Cash Flow
In the last 12 months, operating cash flow was 32.03M and capital expenditures -46.73K, giving a free cash flow of 31.98M billion.
Operating Cash Flow32.03M
Free Cash Flow31.98M
Free Cash Flow per Share1.54
Dividends & Yields
Newron Pharmaceuticals SpA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.88
52-Week Price Change149.42%
50-Day Moving Average17.69
200-Day Moving Average14.55
Relative Strength Index (RSI)37.85
Average Volume (3m)170.30K
Important Dates
Newron Pharmaceuticals SpA upcoming earnings date is Sep 22, 2026, TBA (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateSep 22, 2026
Ex-Dividend Date―
Financial Position
Newron Pharmaceuticals SpA as a current ratio of 0.76, with Debt / Equity ratio of -342.73%
Current Ratio0.76
Quick Ratio0.76
Debt to Market Cap0.07
Net Debt to EBITDA-5.70
Interest Coverage Ratio-1.06
Taxes
In the past 12 months, Newron Pharmaceuticals SpA has paid 885.00K in taxes.
Income Tax885.00K
Effective Tax Rate-0.07
Enterprise Valuation
Newron Pharmaceuticals SpA EV to EBITDA ratio is -117.96, with an EV/FCF ratio of 16.52.
EV to Sales28.09
EV to EBITDA-117.96
EV to Free Cash Flow16.52
EV to Operating Cash Flow16.50
Balance Sheet
Newron Pharmaceuticals SpA has CHF28.85M in cash and marketable securities with CHF38.13M in debt, giving a net cash position of -CHF9.28M billion.
Cash & Marketable SecuritiesCHF28.85M
Total DebtCHF38.13M
Net Cash-CHF9.28M
Net Cash Per Share-CHF0.45
Tangible Book Value Per Share-CHF0.56
Margins
Gross margin is 99.94%, with operating margin of -24.56%, and net profit margin of -69.67%.
Gross Margin99.94%
Operating Margin-24.56%
Pretax Margin-64.59%
Net Profit Margin-69.67%
EBITDA Margin-23.81%
EBIT Margin-24.72%
Analyst Forecast
The average price target for Newron Pharmaceuticals SpA is CHF48.05, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF48.05
Price Target Upside219.51% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast744.64%
EPS Growth Forecast―